Q-omics provides the consensus-scored RPL26P30 profile across patient tissues and cancer cell-line models. RPL26P30 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPL26P30 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, RPL26P30 RNA expression shows 14,521 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and LIHC as cancer lineages where RPL26P30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL26P30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL26P30 survival associations across molecular data types. RPL26P30 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL26P30 RNA expression–survival associations across cancer types. High RPL26P30 expression shows unfavorable associations in UVM, LIHC, ESCA, KIRP and STAD, but favorable associations in COAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RPL26P30 RNA expression.
This table summarizes RPL26P30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL26P30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL26P30 shows lower tumor expression in LUAD and LUSC and higher tumor expression in LIHC, COAD, HNSC and CHOL. The LIHC box plot shows higher RPL26P30 RNA expression in tumor versus normal tissue (log2 FC = +0.380, t-test p < 0.001).
This table shows molecular features associated with RPL26P30 in patient tissues and cancer cell lines. In patient samples, RPL26P30 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
